Neurocrine Biosciences' stock surged 5.86% in pre-market trading on Wednesday, indicating strong investor interest ahead of the regular session.

The significant price movement appears to be driven by the publication of expert recommendations for glucocorticoid dose reduction after initiating Crenessity® (crinecerfont) for the treatment of classic congenital adrenal hyperplasia. This peer-reviewed guidance, published in the Journal of Clinical Endocrinology & Metabolism, provides clinical algorithms that frame Crenessity as enabling more physiologic steroid replacement while maintaining androgen control, which could reduce risks associated with long-term glucocorticoid exposure.

Additionally, the stock received multiple analyst upgrades and positive ratings. Several major financial institutions, including RBC, Piper Sandler, Citigroup, Oppenheimer, Morgan Stanley, and Wedbush, raised their price targets on Neurocrine Biosciences, reflecting growing analyst confidence in the company's prospects.